

AMENDED CLAIMS

121. (Amended) A method for treating a mammal in need of therapy by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

- (1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and
- (2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each [optionally and independently] administered together with a pharmaceutically acceptable carrier or diluent.

127. (Amended) A method of treating a mammal which has been diagnosed as suffering from a condition or the risk of a condition which would benefit from therapy by the combined administration of the active ingredients designated as (a) and (b) below, and therefore administration of both (a) and (b) has been prescribed, which comprises administering to said mammal so diagnosed and prescribed

- (1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and
- (2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each [optionally and independently] administered together with a pharmaceutically acceptable carrier or diluent.

133. (Amended) A method of treating combined hypertension and hyperlipidemia in a mammal which has been examined for both hypertension and hyperlipidemia conditions by a medical practitioner and diagnosed as in need of therapy for said conditions by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each [optionally and independently] administered together with a pharmaceutically acceptable carrier or diluent.

139. (Amended) A method for preventing or reducing cardiac risk in a mammal which has been examined and diagnosed as having symptoms or risk factors for cardiac disease and in need of combined therapy to manage such risk by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) a prophylactically effective amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) a prophylactically effective amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each [optionally and independently] administered together with a pharmaceutically acceptable carrier or diluent.

145. (Amended) A method of treating angina in a mammal which has been examined for angina by a medical practitioner and diagnosed as in need of therapy for said angina by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each [optionally and independently] administered together with a pharmaceutically acceptable carrier or diluent.

151. (Amended) A method of treating atherosclerosis in a mammal which has been examined for atherosclerosis by a medical practitioner and diagnosed as in need of therapy for said atherosclerosis by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each [optionally and independently] administered together with a pharmaceutically acceptable carrier or diluent.